Complex Regional Pain Syndrome Market

Global Complex Regional Pain Syndrome Market Size (2023 to 2028)

The global complex regional pain syndrome market was valued at USD 102.5 million in 2022 and is anticipated to reach USD 118.17 million by 2028 from USD 104.96 million in 2023, growing at a CAGR of 2.4% from 2023 to 2028. 

MARKET DRIVERS:

The growing number of patients suffering from complex regional pain syndrome, chronic pain, and failed back syndrome majorly drive the global market growth. An estimated 280 million have been suffering from complex regional pain syndrome worldwide. Complex regional pain syndrome is a disabling primary pain condition that is associated with swelling, color, temperature and motor changes that normally affect a limb. The treatment for this type of syndrome involves medication, behavioral health intervention, and pain specialist medication and there is rising demand for the treatment of this type of syndrome.

The growing number of R&D activities propel the growth of the complex regional pain syndrome market. Research activities help to improve the diagnosis due to advancements in diagnostic techniques and tools. Timely diagnosis is essential for initiating appropriate treatment and helping to improve patient outcomes. Research helps to target and identify novel therapeutics target for the development of new medications and therapies to treat the complex regional pain syndrome. Such advancements help for better pain relief and symptom management for patients and the innovation in this sector also focuses more on non-invasive intervention, which helps to improve patient compliance and reduce the risk of complications associated with more invasive procedures. Research activities also contribute to development and progression.

An increasing number of initiatives from the governments of several countries for complex regional pain syndrome favors global market growth. The governments of various countries have been playing a major role in supporting the complex regional pain syndrome market by allocating funding support for the research and clinical trials related to complex regional pain syndrome. The support from governmental organizations has been accelerating scientific advancements and resulting in the development of more effective treatment options. The governments have also been putting focus on improving healthcare infrastructure that can benefit patients with complex regional pain syndrome by ensuring better access to healthcare facilities, specialized pain clinics, and majority treatment centers. The governments of some countries have launched public health campaigns to raise awareness about chronic pain conditions and these campaigns lead to earlier detection, diagnosis and timely interventions, thereby helping to improve patient outcomes.

MARKET RESTRAINTS:

Lack of in-depth knowledge of complex regional pain syndrome, the scarcity of medical and behavioral pain management experts, and the lack of effective treatment options majorly limit the growth of the global complex regional pain syndrome market. The exact cause and mechanism of complex regional pain syndrome is not known, which can make accurate diagnosis and targeted treatment more challenging. Thus, the lack of knowledge about this syndrome can lead to misdiagnosis and result in inadequate and ineffective treatment. The management of this syndrome also requires a multidisciplinary approach that involves a medical specialist, pain management expert, and physical therapist, but the shortage of healthcare providers with specialized expertise in this syndrome hampers the global market growth. The lack of effective treatment can leave some individuals with complex regional pain syndrome without adequate pain relief, further impedes the global market growth.

Impact of COVID-19 on the global complex regional pain syndrome market:

The COVID-19 pandemic crisis has had a major impact on every sector due to disruptions in the global supply chains. The measures taken by the governments of several countries to limit the spread of the coronavirus among people, such as lockdowns, social isolation and strict restrictions, have given tough situations to the global trade and supply chains. The COVID-19 pandemic situation has significantly impacted the worldwide complex regional pain syndrome market. During the early stages of the COVID-19 pandemic, virus infection causes peripheral nerve lesions, including small fiber neuropathy. According to a report published by PubMed, systematic hyperinflammation in severe COVID-19 may contribute to peripheral and central neuronal sensitization. This has severely increased the risk of developing complex regional pain syndrome. The coronavirus has a direct effect on neuronal sensitization and there was an emerging demand for drugs used in complex regional pain. Likewise, the global complex regional pain syndrome market has had a favorable impact on the global complex regional pain syndrome market.

REPORT COVERAGE:

This market research report on the global complex regional pain Syndrome market has been segmented based on the disease, drug, distribution channel and region.

Complex Regional Pain Syndrome Market – By Disease Type:

• CRPS I
• CRPS II
• CRPS - NOS

The CRPS-I segment is anticipated to account for the major share of the global market during the forecast period. CRPS-I arises after an injury without any nerve damage. The growing prevalence and incidence of CRPS-I contribute to a larger patient population seeking medical attention and treatment, which drives the demand for CRPS-I-specific medication and therapies. CRPS-I often requires a multidisciplinary approach to treatment involving a pain management specialist, physical therapist, and healthcare professional and this comprehensive management approach leads to a rise in the demand for various medical services and therapies.

The CRPS-II segment is estimated to hold a considerable share of the global market during the forecast period. CRPS-II is another disease caused due to nerve damage or trauma; the rising incidences of nerve injuries due to accidents and surgeries can contribute to the growth of the CRPS-II segment in the global market. Effective pain management is crucial to prevent or minimize the development of CRPS-II in patients with nerve injuries.

Complex Regional Pain Syndrome Market – By Drug Type:

• T-121
• NTRX-07
• Neridronic Acid
• Others

Based on drug type, the neridronic acid drug segment is expected to witness a healthy CAGR during the forecast period. The lack of effective therapies creates an emerging medical need for new and innovative treatment with the help of neridronic acid drugs, driving the growth of the nerodronic acid drug segment in the global market. The potential therapeutic benefit of neridronic acid in CRPS has been investigated in clinical research and trials. Thus, the positive result of this clinical trial generated interest among healthcare providers leading to increased adoption of the drug in clinical practice, propelling the growth of the neridronic acid drug segment in the worldwide market.

The T-121 segment is predicted to occupy a considerable share of the global market during the forecast period owing to the efficacy and safety of T-121 in clinical trials. The significant pain relief and minimal side effects of the T-121 drug would generate more demand among healthcare providers and patients. The regulatory approval by health authorities for the use of T-121 in CRPS fuels the segment’s growth rate.

Complex Regional Pain Syndrome Market – By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Based on the distribution channel, the hospital pharmacy segment is predicted to grow at the fastest CAGR during the forecast period. Hospitals act as a major end-consumer of chronic pain treatment products. Pain management strategies are rising mostly in hospitals, particularly for post-surgical pain, because of the growing number of surgical operations worldwide, which is one of the key factors propelling the growth of the hospital pharmacies segment in the global market.

The online pharmacies segment is expected to account for a notable share of the worldwide market during the forecast period. The COVID-19 pandemic has significantly boosted the adoption of online pharmacies. The growing adoption of digital tools among the population primarily drives the growth of the online pharmacies segment in the global market.

Complex Regional Pain Syndrome Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America is predicted to be the dominating region in the global complex regional pain syndrome market during the forecast period. Factors such as the growing awareness of therapies among patients, the rising prevalence of complex regional pain syndrome, high public and private healthcare spending and easy access to healthcare facilities, and approval of novel drugs majorly drive the complex regional pain syndrome market in North America.

Asia-Pacific was the second-largest regional market for complex regional pain syndrome in 2022 and is anticipated to register the fastest CAGR during the forecast period. The rising healthcare spending in the Asia-Pacific region and the favorable regulatory policies for drug approval propel the APAC market growth.

The European region is anticipated to showcase a healthy CAGR during the forecast period. The high prevalence of complex regional pain syndrome in this region boosts market growth. CRPS affects a considerable number of people in Europe. The rising prevalence of this syndrome contributes to the substantial patient population for proper medical treatment driving the demand for therapies and appropriate treatment, as the rising awareness and diagnosis among patients and healthcare providers regarding the complex regional pain syndrome help to drive the market growth during the projected period. Supportive healthcare infrastructure, emerging research, innovation, favorable regulatory environment are all factors favoring the market's growth in the Europe region.

The Latin American region is also expected to grow at a steady CAGR during the forecast period. Factors such as expanding pharmaceutical industry, rising research and innovation, growing healthcare infrastructure, government initiatives, and clinical trials contribute to the growth of the Latin American market during the forecast period.

The Middle East and Africa region is also expected to register a moderate CAGR during the forecast period. 

KEY MARKET PLAYERS:

Boston Scientific Corporation, and GlaxoSmithKline plc. Johnson & Johnson, Viatris, Sanofi S.A, and Medtronic Plc are some of the major companies in the global complex regional pain syndrome market.

RECENT DEVELOPMENT IN THE MARKET:

• In August 2022, Abbott received approval from the United States FDA for its new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy, which provides tailored relief to multiple pain areas and adds more treatment options for evolving chronic pain conditions.
• In January 2022, Medtronic received United States FDA approval for its Intellis rechargeable neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN). The Intellis rechargeable neurostimulator is also indicated for the intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with Complex Regional Pain Syndrome (CRPS).